Future Treatment Options in PBC

John M. Vierling

doi:10.1055/s-2005-916326

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Semin Liver Dis 2005; 25(3): 347-363
DOI: 10.1055/s-2005-916326

Future Treatment Options in PBC

John M. Vierling¹

¹Professor of Medicine and Surgery, Director, Baylor Liver Health, Chief of Hepatology, Baylor College of Medicine, Houston, Texas

Further Information

Publication History

Publication Date:
06 September 2005 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints

ABSTRACT

Because the etiopathogenesis of PBC is incompletely defined, curative therapies have not been identified, and the focus has been on prevention of disease progression. Ursodeoxycholic acid retards progression and is likely to be combined with newer therapies in future trials. Advances in our understanding of the roles of retroviral infection and autoimmune responses of T and B cells to PBC-specific autoantigens provides rationales for studies of the safety and efficacy of antiretroviral, immunosuppressive, and immunomodulatory agents in PBC. Promising options include inhibition of (1) T-cell activation and proliferation; (2) transendothelial migration and activation of effector cells; (4) cytokine and immunoglobulin effector mechanisms; and (5) inflammation and oxidation. Depletion and immunomodulation of T and B cells may provide opportunities to thwart re-emergence of effector mechanisms. Induction of tolerance in susceptible people before onset of disease or of hyporesponsiveness in established disease is increasingly feasible, as is prevention of biliary fibrosis.

KEYWORDS

Primary biliary cirrhosis - autoantibody - cholestasis - immunopathogenesis - immunosuppression

REFERENCES

1 Vierling J M, Braun M, Wang H-M. Immunopathogenesis of vanishing bile duct syndromes. In: Alpini G, LeSage GD, LaRusso NF Pathophysiology of the Biliary Epithelia Georgetown, TX; Landes Bioscience/Eurekah.com 2003: 349-375

Search in Google Scholar
2 Mato T K, Davis P A, Odin J A, Coppel R L, Gershwin M E. Sidechain biology and the immunogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology. 2004; 40 1241-1248

Crossref PubMed Search in Google Scholar
3 Selmi C, Gershwin M E. Bacteria and human autoimmunity: the case of primary biliary cirrhosis. Curr Opin Rheumatol. 2004; 16 406-410

Crossref PubMed Search in Google Scholar
4 Xu L, Shen Z, Guo L et al.. Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proc Natl Acad Sci USA. 2003; 100 8454-8459

Crossref PubMed Search in Google Scholar
5 Selmi C, Ross S R, Ansari A A et al.. Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis. Gastroenterology. 2004; 127 493-501

Crossref PubMed Search in Google Scholar
6 Ichiki Y, Shimoda S, Ishibashi H, Gershwin M E. Is primary biliary cirrhosis a model autoimmune disease?. Autoimmun Rev. 2004; 3 331-336

Crossref PubMed Search in Google Scholar
7 Kita H, Nalbandian G, Keeffe E B, Coppel R L, Gershwin M E. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis. 2003; 7 821-839

Crossref PubMed Search in Google Scholar
8 Olafsson S, Gudjonsson H, Selmi C et al.. Antimitochondrial antibodies and reactivity to N. aromaticivorans proteins in Icelandic patients with primary biliary cirrhosis and their relatives. Am J Gastroenterol. 2004; 99 2143-2146

Crossref PubMed Search in Google Scholar
9 Long S A, Van De W J, Gershwin M E. Antimitochondrial antibodies in primary biliary cirrhosis: the role of xenobiotics. Autoimmun Rev. 2002; 1 37-42

Crossref PubMed Search in Google Scholar
10 Prince M I, Chetwynd A, Craig W L, Metcalf J V, James O F. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut. 2004; 53 865-870

Crossref PubMed Search in Google Scholar
11 Gottlieb A B. Alefacept is well tolerated in patients with chronic plaque psoriasis. J Cutan Med Surg. 2004; 8(suppl 2) 14-19

Crossref PubMed Search in Google Scholar
12 Zhao S P, Wu J. Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta. 2004; 347 145-150

Crossref PubMed Search in Google Scholar
13 Crisby M. Modulation of the inflammatory process by statins. Drugs Today (Barc). 2003; 39 137-143

Crossref PubMed Search in Google Scholar
14 Vierling J M. Primary biliary cirrhosis and autoimmune cholangiopathy. Clin Liver Dis. 2004; 8 177-194

Crossref PubMed Search in Google Scholar
15 Muratori P, Muratori L, Gershwin M E et al.. ‘True’ antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol. 2004; 135 154-158

Crossref PubMed Search in Google Scholar
16 Shigematsu H, Shimoda S, Nakamura M et al.. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and cross-recognition among mitochondrial autoantigens. Hepatology. 2000; 32 901-909

Crossref PubMed Search in Google Scholar
17 Matsumura S, Kita H, He X S et al.. Comprehensive mapping of HLA-A0201-restricted CD8 T-cell epitopes on PDC-E2 in primary biliary cirrhosis. Hepatology. 2002; 36 1125-1134

Crossref PubMed Search in Google Scholar
18 Albanis E, Safadi R, Friedman S L. Treatment of hepatic fibrosis: almost there. Curr Gastroenterol Rep. 2003; 5 48-56

PubMed Search in Google Scholar
19 Friedman S L. Liver fibrosis-from bench to bedside. J Hepatol. 2003; 38(suppl 1) S38-S53

PubMed Search in Google Scholar
20 Elster E A, Hale D A, Mannon R B, Cendales L C, Swanson S J, Kirk A D. The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. Transpl Immunol. 2004; 13 87-99

PubMed Search in Google Scholar
21 Oo Y H, Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs. 2004; 64 2261-2271

PubMed Search in Google Scholar
22 Lazaridis K N, Gores G J, Lindor K D. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J Hepatol. 2001; 35 134-146

Crossref PubMed Search in Google Scholar
23 Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2002; 1 CD000551

PubMed Search in Google Scholar
24 Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon R E, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005; 128 297-303

Crossref PubMed Search in Google Scholar
25 Corpechot C, Poujol-Robert A, Wendum D et al.. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 2004; 24 187-193

Crossref PubMed Search in Google Scholar
26 Bogdanos D P, Pares A, Baum H et al.. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004; 22 353-362

Crossref PubMed Search in Google Scholar
27 Abdulkarim A S, Petrovic L M, Kim W R, Angulo P, Lloyd R V, Lindor K D. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae?. J Hepatol. 2004; 40 380-384

Crossref PubMed Search in Google Scholar
28 Durazzo M, Rosina F, Premoli A et al.. Lack of association between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis. World J Gastroenterol. 2004; 10 3179-3181

Crossref PubMed Search in Google Scholar
29 Mason A, Xu L, Neuberger J. Proof of principal studies to assess the role of the human betaretrovirus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004; 99 2499-2500

Crossref PubMed Search in Google Scholar
30 Mason A L, Farr G H, Xu L, Hubscher S G, Neuberger J M. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004; 99 2348-2355

Crossref PubMed Search in Google Scholar
31 Hung C C, Chang S C. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother. 2004; 54 849-853

Crossref PubMed Search in Google Scholar
32 Vierling J M, Flores P A. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis. 2002; 6 825-850

PubMed Search in Google Scholar
33 Wiseman H, Duffy R. New advances in the understanding of the role of steroids and steroid receptors in disease. Biochem Soc Trans. 2001; 29(pt 2) 205-209

Crossref PubMed Search in Google Scholar
34 Mitchison H C, Palmer J M, Bassendine M F, Watson A J, Record C O, James O F. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol. 1992; 15 336-344

Crossref PubMed Search in Google Scholar
35 Okamoto R, Yamamoto K, Yabushita K et al.. T cell repertoire in primary biliary cirrhosis: a common T cell clone and repertoire change after treatment. J Clin Immunol. 2001; 21 278-285

Crossref PubMed Search in Google Scholar
36 Mazzella G, Fusaroli P, Pezzoli A et al.. Methylprednisolone administration in primary biliary cirrhosis increases cholic acid turnover, synthesis, and deoxycholate concentration in bile. Dig Dis Sci. 1999; 44 2478-2483

Crossref PubMed Search in Google Scholar
37 Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J Hepatol. 1996; 25 49-57

Crossref PubMed Search in Google Scholar
38 O'Connell E J. Review of the unique properties of budesonide. Clin Ther. 2003; 25(suppl C) C42-C60

Crossref PubMed Search in Google Scholar
39 Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003; 38 196-202

PubMed Search in Google Scholar
40 Leuschner M, Maier K P, Schlichting J et al.. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 1999; 117 918-925

Crossref PubMed Search in Google Scholar
41 Rautiainen H, Karkkainen P, Karvonen A L et al.. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 2005; 41 747-752

Crossref PubMed Search in Google Scholar
42 Angulo P, Jorgensen R A, Keach J C, Dickson E R, Smith C, Lindor K D. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 2000; 31 318-323

Crossref PubMed Search in Google Scholar
43 Jorgensen K A, Koefoed-Nielsen P B, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol. 2003; 57 93-98

Crossref PubMed Search in Google Scholar
44 Jiang S, Herrera O, Lechler R I. New spectrum of allorecognition pathways: implications for graft rejection and transplantation tolerance. Curr Opin Immunol. 2004; 16 550-557

Crossref PubMed Search in Google Scholar
45 Wu H Y, Weiner H L. Oral tolerance. Immunol Res. 2003; 28 265-284

Crossref PubMed Search in Google Scholar
46 Beukers R, de Rave S, van den Berg J W, Schalm S W. Oral pharmacokinetics of cyclosporin in patients with primary biliary cirrhosis and patients with skin diseases. Aliment Pharmacol Ther. 1992; 6 459-468

PubMed Search in Google Scholar
47 Wiesner R H, Ludwig J, Lindor K D et al.. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990; 322 1419-1424

Crossref PubMed Search in Google Scholar
48 Lombard M, Portmann B, Neuberger J et al.. Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology. 1993; 104 519-526

PubMed Search in Google Scholar
49 Guanabens N, Pares A, Navasa M et al.. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol. 1994; 21 24-28

Crossref PubMed Search in Google Scholar
50 Hanley D A, Ayer L M, Gundberg C M, Minuk G Y. Parameters of calcium metabolism during a pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Clin Invest Med. 1991; 14 282-287

PubMed Search in Google Scholar
51 Parsons H G, Thirsk J E, Frohlich J, Dias V, Minuk G Y. Effect of cyclosporin A on serum lipids in primary biliary cirrhosis patients. Clin Invest Med. 1989; 12 386-391

PubMed Search in Google Scholar
52 Robson S C, Neuberger J M, Williams R. The influence of cyclosporine A therapy on sex hormone levels in pre- and post-menopausal women with primary biliary cirrhosis. J Hepatol. 1994; 21 412-416

Crossref PubMed Search in Google Scholar
53 McMichael J, Lieberman R, McCauley J, Irish W, Marino I, Doyle H. Computer-guided randomized concentration-controlled trials of tacrolimus in autoimmunity: multiple sclerosis and primary biliary cirrhosis. Ther Drug Monit. 1996; 18 435-437

Crossref PubMed Search in Google Scholar
54 Thomson A W, Bonham C A, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995; 17 584-591

PubMed Search in Google Scholar
55 Lunz III J G, Contrucci S, Ruppert K et al.. Replicative senescence of biliary epithelial cells precedes bile duct loss in chronic liver allograft rejection: increased expression of p21(WAF1/Cip1) as a disease marker and the influence of immunosuppressive drugs. Am J Pathol. 2001; 158 1379-1390

PubMed Search in Google Scholar
56 Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004; 10 488-491

Crossref PubMed Search in Google Scholar
57 Simon H U, Spath P J. IVIG-mechanisms of action. Allergy. 2003; 58 543-552

Crossref PubMed Search in Google Scholar
58 Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 2001; 62 133-137

Crossref PubMed Search in Google Scholar
59 Skov L, Kragballe K, Zachariae C et al.. HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol. 2003; 139 1433-1439

Crossref PubMed Search in Google Scholar
60 Winsor-Hines D, Merrill C, O’Mahony M et al.. Induction of immunological tolerance/hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol. 2004; 173 4715-4723

PubMed Search in Google Scholar
61 Mileski W J, Burkhart D, Hunt J L et al.. Clinical effects of inhibiting leukocyte adhesion with monoclonal antibody to intercellular adhesion molecule-1 (enlimomab) in the treatment of partial-thickness burn injury. J Trauma. 2003; 54 950-958

PubMed Search in Google Scholar
62 Becker K J. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and Enlimomab (R6.5) in acute stroke. Curr Med Res Opin. 2002; 18(suppl 2) s18-s22

PubMed Search in Google Scholar
63 Dedrick R L, Walicke P, Garovoy M. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transpl Immunol. 2002; 9 181-186

PubMed Search in Google Scholar
64 Leonardi C L, Papp K A, Gordon K B et al.. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005; 52(3 pt 1) 425-433

Crossref PubMed Search in Google Scholar
65 Menter A, Gordon K, Carey W et al.. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005; 141 31-38

Crossref PubMed Search in Google Scholar
66 Najafian N, Sayegh M H. CTLA4-Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs. 2000; 9 2147-2157

Crossref PubMed Search in Google Scholar
67 Li S, Thanikachalam M, Pang M, Kawaharada N, Aitouche A, Pham S M. A clinically relevant CTLA4-Ig-based regimen induces chimerism and tolerance to heart grafts. Ann Thorac Surg. 2001; 72 1306-1310

Crossref PubMed Search in Google Scholar
68 Hodak E, David M. Alefacept: a review of the literature and practical guidelines for management. Dermatol Ther. 2004; 17 383-392

Crossref PubMed Search in Google Scholar
69 Liu C M, McKenna J K, Krueger G G. Alefacept: a novel biologic in the treatment of psoriasis. Drugs Today (Barc). 2004; 40 961-974

Crossref PubMed Search in Google Scholar
70 Gordon K B, Valentine J. The efficacy of alefacept in the treatment of chronic plaque psoriasis. J Cutan Med Surg. 2004; 8(suppl 2) 3-9

PubMed Search in Google Scholar
71 Grewal I S, Flavell R A. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996; 153 85-106

Crossref PubMed Search in Google Scholar
72 Elster E A, Xu H, Tadaki D K et al.. Treatment with the humanized CD154-specific monoclonal antibody, hu5C8, prevents acute rejection of primary skin allografts in nonhuman primates. Transplantation. 2001; 72 1473-1478

PubMed Search in Google Scholar
73 Xu H, Tadaki D K, Elster E A et al.. Humanized anti-CD154 antibody therapy for the treatment of allograft rejection in nonhuman primates. Transplantation. 2002; 74 940-943

PubMed Search in Google Scholar
74 Starck L, Scholz C, Dorken B, Daniel P T. Costimulation by CD137/4-1BB inhibits T cell apoptosis and induces Bcl-x(L) and c-FLIP(short) via phosphatidylinositol 3-kinase and AKT/protein kinase B. Eur J Immunol. 2005; 35 1257-1266

Crossref PubMed Search in Google Scholar
75 Shao H, Fu Y, Liao T et al.. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells. Invest Ophthalmol Vis Sci. 2005; 46 596-603

Crossref PubMed Search in Google Scholar
76 Rowinsky E K. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2004; 16 564-575

PubMed Search in Google Scholar
77 Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs. 2002; 11 1845-1857

Crossref PubMed Search in Google Scholar
78 Kahan B D. Sirolimus-based immunosuppression: present state of the art. J Nephrol. 2004; 17(suppl 8) S32-S39

PubMed Search in Google Scholar
79 Niemeyer G, Koch M, Light S, Kuse E R, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant. 2002; 2 454-460

Crossref PubMed Search in Google Scholar
80 Kapic E, Becic F, Kusturica J. Basiliximab, mechanism of action and pharmacological properties. Med Arh. 2004; 58 373-376

PubMed Search in Google Scholar
81 Baudouin V, Crusiaux A, Haddad E et al.. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation. 2003; 76 459-463

PubMed Search in Google Scholar
82 Bielekova B, Richert N, Howard T et al.. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA. 2004; 101 8705-8708

Crossref PubMed Search in Google Scholar
83 Van Assche G, Dalle I, Noman M et al.. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am J Gastroenterol. 2003; 98 369-376

PubMed Search in Google Scholar
84 Lee S J, Zahrieh D, Agura E et al.. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004; 104 1559-1564

Crossref PubMed Search in Google Scholar
85 Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002; 30 899-903

Crossref PubMed Search in Google Scholar
86 Heathcote E J. Evidence-based therapy of primary biliary cirrhosis. Eur J Gastroenterol Hepatol. 1999; 11 607-615

PubMed Search in Google Scholar
87 Moder K G. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol. 2003; 90 15-19

PubMed Search in Google Scholar
88 Jones E A. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis. Hepatology. 2002; 35 258-262

Crossref PubMed Search in Google Scholar
89 Talwalkar J A, Angulo P, Keach J C, Petz J L, Jorgensen R A, Lindor K D. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. J Clin Gastroenterol. 2005; 39 168-171

PubMed Search in Google Scholar
90 Maddison P, Kiely P, Kirkham B et al.. Leflunomide in rheumatoid arthritis: recommendations through a process of consensus. Rheumatology (Oxford). 2005; 44 280-286

Crossref PubMed Search in Google Scholar
91 Grisar J, Aringer M, Koller M D et al.. Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis. 2004; 63 1632-1637

Crossref PubMed Search in Google Scholar
92 Cannon G W, Holden W L, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumatol. 2004; 31 1906-1911

PubMed Search in Google Scholar
93 Laborde F, Loeuille D, Chary-Valckenaere I. Life-threatening hypertriglyceridemia during leflunomide therapy in a patient with rheumatoid arthritis. Arthritis Rheum. 2004; 50 3398

PubMed Search in Google Scholar
94 Macdonald J, Zhong T, Lazarescu A, Gan B S, Harth M. Vasculitis associated with the use of leflunomide. J Rheumatol. 2004; 31 2076-2078

PubMed Search in Google Scholar
95 Sevilla-Mantilla C, Ortega L, Agundez J A, Fernandez-Gutierrez B, Ladero J M, Diaz-Rubio M. Leflunomide-induced acute hepatitis. Dig Liver Dis. 2004; 36 82-84

Crossref PubMed Search in Google Scholar
96 Kremer J M, Cannon G W. Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol. 2004; 22(5 suppl 35) S95-100

PubMed Search in Google Scholar
97 Korn T, Magnus T, Toyka K, Jung S. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide-mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004; 76 950-960

Crossref PubMed Search in Google Scholar
98 Yao H W, Li J, Chen J Q, Xu S Y. Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells. World J Gastroenterol. 2004; 10 1608-1611

PubMed Search in Google Scholar
99 Schrepfer S, Deuse T, Schafer H, Reichenspurner H. FK778, a novel immunosuppressive agent, reduces early adhesion molecule up-regulation and prolongs cardiac allograft survival. Transpl Int. 2005; 18 215-220

Crossref PubMed Search in Google Scholar
100 Vanrenterghem Y, van Hooff J P, Klinger M et al.. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation. 2004; 78 9-14

PubMed Search in Google Scholar
101 Xu D, Alegre M L, Varga S S et al.. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol. 2000; 200 16-26

Crossref PubMed Search in Google Scholar
102 Popma S H, Griswold D E, Li L. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; a specific T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells. Int Immunopharmacol. 2005; 5 155-162

PubMed Search in Google Scholar
103 Kjer-Nielsen L, Dunstone M A, Kostenko L et al.. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3. Proc Natl Acad Sci USA. 2004; 101 7675-7680

Crossref PubMed Search in Google Scholar
104 Carpenter P A, Tso J Y, Press O W, Yu X, Anasetti C. Non-FcR-binding, humanized anti-CD3 antibody Hu291 induces apoptosis of human T cells more effectively than OKT3 and is immunosuppressive in vivo. Transplant Proc. 2000; 32 1545-1546

Crossref PubMed Search in Google Scholar
105 Ravandi F. O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther. 2005; 5 39-51

Crossref PubMed Search in Google Scholar
106 Marcos A, Eghtesad B, Fung J J et al.. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation. 2004; 78 966-971

Crossref PubMed Search in Google Scholar
107 Iannitto E, Minardi V, Calvaruso G et al.. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol. 2005; 74 254-258

Crossref PubMed Search in Google Scholar
108 Cannon G W, Kremer J M. Leflunomide. Rheum Dis Clin North Am. 2004; 30 295-309

Crossref PubMed Search in Google Scholar
109 Migita K, Miyashita T, Ishibashi H et al.. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts. Clin Exp Immunol. 2004; 137 612-616

Crossref PubMed Search in Google Scholar
110 Brinkmann V. FTY720: mechanism of action and potential benefit in organ transplantation. Yonsei Med J. 2004; 45 991-997

PubMed Search in Google Scholar
111 Muller H, Hofer S, Kaneider N et al.. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur J Immunol. 2005; 35 533-545

Crossref PubMed Search in Google Scholar
112 Lee W J, Yoo H S, Suh P G, Oh S, Lim J S, Lee Y M. Sphingosine mediates FTY720-induced apoptosis in LLC-PK1 cells. Exp Mol Med. 2004; 36 420-427

PubMed Search in Google Scholar
113 Nagahara Y, Ikekita M, Shinomiya T. T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Pharmacol. 2002; 137 953-962

Crossref PubMed Search in Google Scholar
114 Kita Y, Li X K, Nogimura H et al.. CTLA4Ig-gene transfection with FTY720 administration markedly inhibits the obliterative airway disease in heterotopically transplanted rat tracheas. Transplant Proc. 2003; 35 458-460

Crossref PubMed Search in Google Scholar
115 Kimura T, Hasegawa T, Nakai H et al.. FTY720 reduces T-cell recruitment into murine intestinal allograft and prevents activation of graft-infiltrating cells. Transplantation. 2003; 75 1469-1474

PubMed Search in Google Scholar
116 Han S, Zhang X, Wang G et al.. FTY720 suppresses humoral immunity by inhibiting germinal center reaction. Blood. 2004; 104 4129-4133

Crossref PubMed Search in Google Scholar
117 Koyrakh L, Roman M I, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant. 2005; 5 529-536

Crossref PubMed Search in Google Scholar
118 Anonymous. Natalizumab: AN 100226, anti-4alpha integrin monoclonal antibody. Drugs R D. 2004; 5 102-107

PubMed Search in Google Scholar
119 Miller D H, Khan O A, Sheremata W A et al.. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348 15-23

Crossref PubMed Search in Google Scholar
120 Ghosh S, Goldin E, Gordon F H et al.. Natalizumab for active Crohn’s disease. N Engl J Med. 2003; 348 24-32

PubMed Search in Google Scholar
121 In Brief. Natalizumab (Tysabri) withdrawn. Med Lett Drugs Ther. 2005; 47 21

PubMed Search in Google Scholar
122 Fernandez E J, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002; 42 469-499

Crossref PubMed Search in Google Scholar
123 Kamihira T, Shimoda S, Nakamura M et al.. Biliary epithelial cells regulate autoreactive T cells: implications for biliary-specific diseases. Hepatology. 2005; 41 151-159

Crossref PubMed Search in Google Scholar
124 Shaw J P, Johnson Z, Borlat F et al.. The X-ray structure of RANTES: heparin-derived disaccharides allows the rational design of chemokine inhibitors. Structure (Camb). 2004; 12 2081-2093

Crossref PubMed Search in Google Scholar
125 Matsui M, Weaver J, Proudfoot A E et al.. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol. 2002; 128 16-22

Crossref PubMed Search in Google Scholar
126 Sigrist S, Oberholzer J, Bohbot A et al.. Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids. Immunology. 2004; 111 416-421

Crossref PubMed Search in Google Scholar
127 Kawamura T, Bruse S E, Abraha A et al.. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes. J Virol. 2004; 78 7602-7609

Crossref PubMed Search in Google Scholar
128 Foster-Cuevas M, Wright G J, Puklavec M J, Brown M H, Barclay A N. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol. 2004; 78 7667-7676

Crossref PubMed Search in Google Scholar
129 Song E, Zou H, Yao Y et al.. Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int. 2002; 61 676-685

Crossref PubMed Search in Google Scholar
130 Bedke J, Stojanovic T, Grone H J et al.. Met-RANTES improves acute-rejection-induced microvascular injury in rat small bowel transplantation. Transplant Proc. 2002; 34 1049

Crossref PubMed Search in Google Scholar
131 Chvatchko Y, Proudfoot A E, Buser R et al.. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol. 2003; 171 5498-5506

PubMed Search in Google Scholar
132 Heise C E, Pahuja A, Hudson S C et al.. Pharmacological Characterization of CXC Chemokine Receptor 3 (CXCR3) Ligands and a Small-Molecule Antagonist. J Pharmacol Exp Ther. 2005; 313 1263-1271

Crossref PubMed Search in Google Scholar
133 Belperio J A, Keane M P, Burdick M D et al.. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol. 2003; 171 4844-4852

Crossref PubMed Search in Google Scholar
134 Schreiber S, Fedorak R N, Nielsen O H et al.. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn’s disease. Crohn’s Disease IL-10 Cooperative Study Group. Gastroenterology. 2000; 119 1461-1472

Crossref PubMed Search in Google Scholar
135 Rea D, Laface D, Hutchins B et al.. Recombinant adenovirus-transduced human dendritic cells engineered to secrete interleukin-10 (IL-10) suppress Th1-type responses while selectively activating IL-10-producing CD4+ T cells. Hum Immunol. 2004; 65 1344-1355

Crossref PubMed Search in Google Scholar
136 Shen C, Assche G V, Colpaert S et al.. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005; 21 251-258

Crossref PubMed Search in Google Scholar
137 van den Brande J, Hommes D W, Peppelenbosch M P. Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol. 2005; 74(suppl) 26-30

PubMed Search in Google Scholar
138 Tak P P. Effects of infliximab treatment on rheumatoid synovial tissue. J Rheumatol Suppl. 2005; 74 31-34

PubMed Search in Google Scholar
139 Doty J D, Mazur J E, Judson M A. Treatment of sarcoidosis with infliximab. Chest. 2005; 127 1064-1071

Crossref PubMed Search in Google Scholar
140 Baker D E. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev Gastroenterol Disord. 2004; 4 196-210

PubMed Search in Google Scholar
141 Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler L E. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. Joint Bone Spine. 2004; 71 601-603

Crossref PubMed Search in Google Scholar
142 Papadakis K A, Shaye O A, Vasiliauskas E A et al.. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am J Gastroenterol. 2005; 100 75-79

Crossref PubMed Search in Google Scholar
143 Nanda S, Bathon J M. Etanercept: a clinical review of current and emerging indications. Expert Opin Pharmacother. 2004; 5 1175-1186

Crossref PubMed Search in Google Scholar
144 Simonini G, Giani T, Stagi S, de Martino M, Falcini F. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford). 2005; 44 777-780

Crossref PubMed Search in Google Scholar
145 Lebwohl M G. Use of etanercept in the dermatology setting. A review. Am J Clin Dermatol. 2005; 6 49-59

PubMed Search in Google Scholar
146 Zein N N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005; 42 315-322

Crossref PubMed Search in Google Scholar
147 Taal B G, Schalm S W, de Bruyn A M, de Rooy F W, Klein F. Serum IgM in primary biliary cirrhosis. Clin Chim Acta. 1980; 108 457-463

Crossref PubMed Search in Google Scholar
148 Krams S M, Van De W J, Coppel R L et al.. Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary biliary cirrhosis. Hepatology. 1990; 12 306-313

PubMed Search in Google Scholar
149 Kita H, Imawari M, Gershwin M E. Cellular immune response in primary biliary cirrhosis. Hepatol Res. 2004; 28 12-17

PubMed Search in Google Scholar
150 Rastetter W, Molina A, White C A. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med. 2004; 55 477-503

Crossref PubMed Search in Google Scholar
151 Horning S J. Optimizing rituximab in B-cell lymphoma. J Clin Oncol. 2005; 23 1056-1058

Crossref PubMed Search in Google Scholar
152 Gordan L N, Grow W B, Pusateri A, Douglas V, Mendenhall N P, Lynch J W. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005; 23 1096-1102

Crossref PubMed Search in Google Scholar
153 Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother. 2004; 58 299-309

Crossref PubMed Search in Google Scholar
154 Looney R J, Anolik J H, Campbell D et al.. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004; 50 2580-2589

Crossref PubMed Search in Google Scholar
155 Gottenberg J, Guillevin L, Lambotte O et al.. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2004; 64 913-920

PubMed Search in Google Scholar
156 Kita H, Lian Z X, Van De W J et al.. Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. J Exp Med. 2002; 195 113-123

Crossref PubMed Search in Google Scholar
157 Fazio S, Linton M F. The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004; 6 148-157

PubMed Search in Google Scholar
158 Chang P Y, Lu S C, Su T C et al.. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res. 2004; 45 2116-2122

PubMed Search in Google Scholar
159 Matsumoto T, Miyazaki H, Nakahashi Y et al.. Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res. 2004; 30 125-136

Crossref PubMed Search in Google Scholar
160 Itakura J, Izumi N, Nishimura Y et al.. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol Res. 2004; 29 216-222

Crossref PubMed Search in Google Scholar
161 Hays T, Rusyn I, Burns A M et al.. Role of peroxisome proliferator-activated receptor-alpha (PPARalpha) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis. 2005; 26 219-227

PubMed Search in Google Scholar
162 Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K. Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004; 10 894-898

Crossref PubMed Search in Google Scholar
163 Ho C Y, Kuo T H, Chen T S, Tsay S H, Chang F Y, Lee S D. Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc. 2004; 67 245-247

PubMed Search in Google Scholar
164 Ahmed F, Petrovic L, Rosen E, Gonzalez R, Jacobson I M. Fenofibrate-induced cirrhosis. Dig Dis Sci. 2005; 50 312-313

Crossref PubMed Search in Google Scholar
165 Parnes S M. The role of leukotriene inhibitors in patients with paranasal sinus disease. Curr Opin Otolaryngol Head Neck Surg. 2003; 11 184-191

Crossref PubMed Search in Google Scholar
166 Nakamura A, Yamazaki K, Suzuki K, Sato S. Increased portal tract infiltration of mast cells and eosinophils in primary biliary cirrhosis. Am J Gastroenterol. 1997; 92 2245-2249

PubMed Search in Google Scholar
167 Obase Y, Shimoda T, Matsuse H et al.. The position of pranlukast, a cysteinyl leukotriene receptor antagonist, in the long-term treatment of asthma. 5-year follow-up study. Respiration. 2004; 71 225-232

Crossref PubMed Search in Google Scholar
168 Joshi E M, Heasley B H, Chordia M D, Macdonald T L. In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity. Chem Res Toxicol. 2004; 17 137-143

Crossref PubMed Search in Google Scholar
169 Su C W, Wu J C, Huang Y H, Huang Y S, Chang F Y, Lee S D. Zafirlukast-induced acute hepatitis. Zhonghua Yi Xue Za Zhi (Taipei). 2002; 65 553-556

PubMed Search in Google Scholar
170 Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology. 2001; 57 1428-1434

Crossref PubMed Search in Google Scholar
171 Goldstein M F, Anoia J, Black M. Montelukast-induced hepatitis. Ann Intern Med. 2004; 140 586-587

PubMed Search in Google Scholar
172 Fukushima C, Matsuse H, Hishikawa Y et al.. Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol. 2005; 136 165-172

Crossref PubMed Search in Google Scholar
173 Ishinaga H, Takeuchi K, Kishioka C, Suzuki S, Basbaum C, Majima Y. Pranlukast inhibits NF-kappaB activation and MUC2 gene expression in cultured human epithelial cells. Pharmacology. 2005; 73 89-96

Crossref PubMed Search in Google Scholar
174 Ichiyama T, Hasegawa S, Umeda M, Terai K, Matsubara T, Furukawa S. Pranlukast inhibits NF-kappa B activation in human monocytes/macrophages and T cells. Clin Exp Allergy. 2003; 33 802-807

Crossref PubMed Search in Google Scholar
175 Liu K H, Lee Y M, Shon J H et al.. Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004; 34 429-438

Crossref PubMed Search in Google Scholar
176 Shimbo J, Onodera O, Tanaka K, Tsuji S. Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast. Clin Rheumatol. 2004; 23 581-582

PubMed Search in Google Scholar
177 Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol. 2004; 13 117-130

PubMed Search in Google Scholar
178 Sayegh M H, Perico N, Remuzzi G. Transplantation tolerance. A complex scenario awaiting clinical applicability. Contrib Nephrol. 2005; 146 95-104

PubMed Search in Google Scholar
179 Mayer L, Shao L. Therapeutic potential of oral tolerance. Nat Rev Immunol. 2004; 4 407-419

Crossref PubMed Search in Google Scholar
180 Lu L, Thomson A W. Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease. Transplantation. 2002; 73(1 suppl) S19-S22

PubMed Search in Google Scholar
181 Xiao B G, Huang Y M, Link H. Dendritic cell vaccine design: strategies for eliciting peripheral tolerance as therapy of autoimmune diseases. BioDrugs. 2003; 17 103-111

PubMed Search in Google Scholar
182 Suzuki A. Van De WJ, Gershwin ME, Jorgensen R, Angulo P, Lindor K. Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol. 2002; 9 55-61

PubMed Search in Google Scholar
183 Amano K, Leung P S, Xu Q et al.. Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J Immunol. 2004; 172 6444-6452

PubMed Search in Google Scholar
184 Timmerman J M, Czerwinski D K, Davis T A et al.. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002; 99 1517-1526

Crossref PubMed Search in Google Scholar
185 Wright G J, Cherwinski H, Foster-Cuevas M et al.. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol. 2003; 171 3034-3046

PubMed Search in Google Scholar
186 Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden P A. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol. 2004; 172 7744-7749

PubMed Search in Google Scholar
187 Jiang S, Lechler R I. Regulatory T cells in the control of transplantation tolerance and autoimmunity. Am J Transplant. 2003; 3 516-524

Crossref PubMed Search in Google Scholar
188 Walsh P T, Taylor D K, Turka L A. Tregs and transplantation tolerance. J Clin Invest. 2004; 114 1398-1403

Crossref PubMed Search in Google Scholar
189 Bataller R, Brenner D A. Liver fibrosis. J Clin Invest. 2005; 115 209-218

Crossref PubMed Search in Google Scholar
190 Clouston A D, Powell E E, Walsh M J, Richardson M M, Demetris A J, Jonsson J R. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology. 2005; 41 809-818

Crossref PubMed Search in Google Scholar

John M VierlingM.D. F.A.C.P.

Baylor Liver Health, Baylor College of Medicine

6550 Fannin, Suite 1661

Houston, TX 77030

Email: vierling@bcm.tmc.edu